• 1
    Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343: 162733.
  • 2
    Kendal WS. Chance mechanisms affecting the burden of metastases. BMC Cancer. 2005;5: 138.
  • 3
    Swensen S, Aberle CD, Kazerooni EA, et al. Consensus statement: CT screening for lung cancer. J Thorac Imaging. 2005;20: 321.
  • 4
    Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2008) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6: e1000097.
  • 5
    Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003;362: 5937.
  • 6
    Lindell RM, Hartman TE, Swensen SJ, et al. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. Am J Roentgenol. 2005;185: 12631.
  • 7
    Marom EM, Sarvis S, Herndon JE II, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223: 4539.
  • 8
    Pastorino U, Landoni C, Marchianò A, et al. Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol. 2009;4: 13526.
  • 9
    Kagna O, Solomonov A, Keidar Z, et al. The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer. Eur J Nucl Med Mol Imaging. 2009;36: 9971004.
  • 10
    Schöder H, Gönen M. Screening for cancer with PET and PET/CT: Potential and Limitations. J Nucl Med. 2007;48(Suppl. 1): 4S18S.
  • 11
    Gomez M, Silvestri GA. Lung cancer screening. Am J Med Sci. 2008;335: 4650.
  • 12
    Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax. 2011;66: 31519.
  • 13
    ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38: 1197.
  • 14
    Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37: 181200.
  • 15
    Weng MJ, Wu MT, Pan HB, et al. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin Imaging. 2004;28: 40814.